Mixture therapy ‘huge enchancment’ in DLBCL care
October 07, 2025
1 min watch
On this video, Tycel Phillips, MD, discusses preliminary outcomes of a section 1b scientific trial targeted on treating diffuse giant B-cell lymphoma with a bispecific antibody and antibody-drug conjugate mixture.
The findings have been offered on the Society of Hematologic Oncology’s Annual Assembly.
“That is one thing, ideally, that perhaps we are able to discover in early strains of remedy with sufferers,” Phillips, affiliate professor within the division of hematology and hematopoietic cell transplantation at Metropolis of Hope, mentioned.
The LOTIS-7 trial is evaluating the mix of loncastuximab tesirine-lpyl (Zynlonta, ADC Therapeutics) plus glofitamab-gxbm (Columvi, Genentech) amongst sufferers with relapsed or refractory diffuse giant B-cell lymphoma who had acquired a minimum of one systematic remedy.
The researchers discovered that the mix had a “manageable” security profile and an entire response price of 90.9% amongst 22 efficacy-evaluable sufferers.
“If we have a look at traditionally what has been reported with glofitamab alone, this was an enormous enchancment within the security of this treatment, and form of suits with the theme we’ve seen earlier than, the place antibody-drug conjugates appear to boost the efficacy and the protection of bispecific antibodies,” Phillips mentioned.
Sources/Disclosures
Supply:
Healio Interviews
Reference:
Alderuccio JP, et al. Summary ABCL-777. Offered at: SOHO Annual Assembly; Sept. 3-6, 2025; Houston.
Disclosures:
ADC Therapeutics funded the research. Phillips experiences no related monetary disclosures.
